China in Africa

China Bio news release, Oct. 28, 2014

In a talk at China’s 18th Biopharmaceutical Drug Development Forum held in Beijing, VP Luo Lu SONG stated that China may have as many as 25 % of the world’s cancer patients, but therapy is mostly based on traditional chemotherapy, and Chinese patients share only a few percent of the global cancer therapy market based on modern targeted therapy or antitumor antibodies.

The group is the world’s largest production base for alginic acid and sodium alginate, for applications in food, medicine and technology. With support from a range of national and provincial programs, the company is now building a large R&D center in Qingdao. The focus will be on food applications through Jihai Nutrition Technologies Co., on marine cosmetics and fertilizers. Functional sugar alcohols are another field of business.

China Bio news release, Oct. 27. 2014

The group of Dongzhi WEI at ECUST has made major developments in steroid biotransformation and has, e. g., produced megestrol, a C20 steroid intermediate, at levels of 60 g/L or higher.

China Bio news release, Oct. 27, 2014

With a total investment of about 14 billion Yuan over three phases, supported by Henan Coal Chemical Group and Qinghai Province, eventually 4,65 mill to/y of coal will be turned into 800.000 t of fuel methanol and 60.000 t of methanol yeast, and 3500 jobs will be created.

China Bio news release, Oct. 24, 2014

The daily output of the pilot plant used for this feasibility study will be just up to 650 l/day, but market expectations are 1,8 billion l of cooking oil to aviation biofuel per year.

China Bio news release, Oct. 24, 2014

The group around Xiyun YAN reported that doxorubicin encaged in H-ferritin nanocages was able to inhibit tumor growth in model mice with a single-dose treatment.

CAS news release, Oc. 24, 2014

The storage of samples from patients suffering from major diseases was started in 2009 by the Capital Medical University and is supported by 14 hospitals. There is cooperation with BGI and the National Gene Bank in Shenzhen.

China Bio news release, Oct. 23, 2014

The enzyme, “Brewers Clarex”, is a proline-specific endoprotease that prevents the formation of chill-haze on beer storage.

China Bio news release, Oct. 22, 2014

Using high-resolution x-ray crystallography, the enzyme, which is important for detoxification, has been shown to release its products via a different exit channel which can be engineered to accommodate bulky substrates better

CAS news release, Oct. 22, 2014

Investment from Yiling will be 15 Mill. Yuan, and the focus will be on prognosis for various cancer risks.

CAS news release, Oct. 20, 2014

The problem is especially pronounced with respect to soybeans. 50 million tons of soybean are imported from the US, Brazil and Argentina, mostly genetically modified. The acreage required to produce this quantity would be 400 mill acres of arable land, close to the current acreage of corn or rice. Harvest increase by breeding, including GEM, would be a solution

China Bio news release, Oct. 20, 2014

The 3-day seminar from Oct. 15-18 brought together about 100 experts and scholars from SE Asia, the Near East and Africa. The focus was on systems biology, synthetic biology, cell factories, pharmaceutical biotechnology and sustainable development.

CAS news release, Oct. 18, 2014

The focus will be on biopharmaceuticals, rare diseases, vaccines and animal health. The China-based operation will employ 1,400 people, said Frank Jiang, Sanofi’s head of R&D in Asia-Pacific.

CAS news release, Oct. 17, 2014

52 years old member of the CAE, Professor at China Agricultural University and Director of a State Key Laboratory, specialist in animal cloning, was relegated from the CAS for reasons of “corruption”. He is accused to have misappropriated public funding to start private companies or funds.

China Bio news release, Oct. 16, 2014